Last reviewed · How we verify
Sorafenib - Period 3
At a glance
| Generic name | Sorafenib - Period 3 |
|---|---|
| Also known as | Regimen A (reference) |
| Sponsor | Xspray Pharma AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. (PHASE2)
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (PHASE2)
- Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects (PHASE1)
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (PHASE2, PHASE3)
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma (PHASE2)
- TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer (PHASE2, PHASE3)
- Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) (PHASE1)
- Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib - Period 3 CI brief — competitive landscape report
- Sorafenib - Period 3 updates RSS · CI watch RSS
- Xspray Pharma AB portfolio CI